首页> 外文期刊>Journal of cosmetic dermatology >The efficacy and tolerability of 5-aminolevulinic acid 5% thermosetting gel photodynamic therapy (PDT) in the treatment of mild-to-moderate acne vulgaris. A two-center, prospective assessor-blinded, proof-of-concept study
【24h】

The efficacy and tolerability of 5-aminolevulinic acid 5% thermosetting gel photodynamic therapy (PDT) in the treatment of mild-to-moderate acne vulgaris. A two-center, prospective assessor-blinded, proof-of-concept study

机译:5-氨基乙酰丙烯酸5%热固性凝胶光动力治疗(PDT)治疗温和至中等痤疮的疗效和耐受性。 一个双中心,前瞻性评估杂乱,概念证明研究

获取原文
获取原文并翻译 | 示例

摘要

Background Acne vulgaris is a chronic inflammatory skin disease, commonly treated with topical or systemic drugs, according to the severity of the condition. Retinoids and antibiotic compounds are considered cornerstone approaches in this condition. However, low adherence to the therapy and the issue of bacterial resistance undermine the efficacy in the long term. Photodynamic therapy (PDT) with 20% aminolevulinic acid (ALA) has shown to be effective in the treatment of inflammatory acne. Skin tolerability, however, could be a limiting factor for a widespread use of this approach. A new formulation of 5% ALA in thermosetting gel has been recently available. This formulation allows a more convenient application procedure without occlusion and better and more efficient release of the active compound in comparison with traditional ALA formulations like creams or ointments. Study aim To evaluate in a two-center, assessor-blinded, prospective, proof-of-concept study, the efficacy, and tolerability of red-light (630 nm) PDT with a new 5-ALA "low-dose" topical gel formulation (5%) in the treatment of inflammatory mild-to-moderate acne vulgaris (AV). Subjects and methods A total of 35 subjects with moderate AV of the face (mean age: 24 +/- 8 years, 13 men and 22 women) were enrolled, after their written informed consent. The primary outcome was the evolution of GAG (Global Acne Grade System) score at baseline and after an average of three, 630-nm, 15-minute, PDT sessions, performed every 2 weeks. GAG score was also calculated in a follow-up visit 6 months after the last PDT session. Skin tolerability was assessed during PDT sessions with a patient-reported discomfort level evaluation score from 0 (no discomfort at all) to 3 (severe discomfort). Results At baseline, the GAG score was 21 +/- 6. After the last PDT session, the GAG score evaluated in a blinded fashion (digital photographs) was significantly reduced to 6.5 +/- 5.7, representing a 70% reduction (P = .0001, Wilcoxon test; mean difference 14.9; 95% CI of the difference: 12.1-17.6). At the follow-up visit, the GAG score was 6.7 +/- 6.8. The 5% ALA thermosetting gel Red-light PDT was in general very well tolerated with a discomfort mean level score of 0.5 +/- 1. Conclusion This proof-of-concept study supports the efficacy of 5% ALA thermosetting gel red-light PDT in inflammatory acne of the face with a relevant clinical improvement of inflammatory lesions with a very good tolerability profile. Clinical improvement was maintained in the medium term (Trial Registration Number: ISRCTN66066651).
机译:背景技术祛痘是一种慢性炎症皮肤病,通常用局部或全身药物治疗,根据病情的严重程度。在这种情况下,类视黄醇和抗生素化合物被认为是基石。然而,对治疗的低依从性和细菌抗性问题长期破坏了疗效。具有20%氨基乙酰丙酸(ALA)的光动力疗法(PDT)显示有效地治疗炎性痤疮。然而,皮肤耐受性可能是广泛使用这种方法的限制因素。最近可获得热固性凝胶中5%ALA的新配方。该制剂允许更方便的施用过程而没有闭塞,并且与乳膏或软膏等传统ALA制剂相比,活性化合物更好且更高效地释放。研究旨在评估在双方,评估别盲,前瞻性,概念证据研究,红光(630nm)PDT的疗效和耐受性与新的5 - Ala“低剂量”局部凝胶制剂(5%)治疗炎性轻度至中度痤疮寻常(AV)。主题和方法共有35名受试者,脸部的适度AV(平均:24 +/- 8岁,13名男子和22名女性)在其书面知情同意之后注册。主要结果是基线的Gag(全球痤疮级系统)评分的演变,并且在平均三个,630纳米,15分钟,PDT会话中每2周进行一次。在最后一次PDT会话后6个月后,GAG评分也在后续访问中计算。在PDT会话期间评估皮肤耐受性,患者报告的不适水平评估得分从0(根本没有不适)至3(严重的不适)。结果在基线,GAG评分为21 +/- 6.在最后的PDT会话之后,以盲目的方式(数字照片)评估的GAG评分显着降至6.5 +/- 5.7,表示减少70%(P = .0001,Wilcoxon试验;平均差异14.9; 95%CI差异:12.1-17.6)。在后续访问中,GAG得分为6.7 +/- 6.8。 5%Ala热固性凝胶红光PDT一般耐受性,不适的平均水平得分为0.5 +/- 1.结论该概念证据研究支持5%ALA热固性凝胶红光PDT的疗效在面部炎性痤疮中,具有具有非常好的耐受性曲线的炎性病变的相关临床改善。中期维持临床改善(试验登记号:ISRCTN6606651)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号